These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35138335)

  • 1. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
    Reijers ILM; Rawson RV; Colebatch AJ; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Wouters MW; Saw RPM; van Houdt WJ; Zuur CL; Nieweg OE; Ch'ng S; Klop WMC; Spillane AJ; Long GV; Scolyer RA; van de Wiel BA; Blank CU
    JAMA Surg; 2022 Apr; 157(4):335-342. PubMed ID: 35138335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
    Reijers ILM; Menzies AM; van Akkooi ACJ; Versluis JM; van den Heuvel NMJ; Saw RPM; Pennington TE; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Rozeman EA; Klop WMC; van Houdt WJ; Sikorska K; van der Hage JA; Grünhagen DJ; Wouters MW; Witkamp AJ; Zuur CL; Lijnsvelt JM; Torres Acosta A; Grijpink-Ongering LG; Gonzalez M; Jóźwiak K; Bierman C; Shannon KF; Ch'ng S; Colebatch AJ; Spillane AJ; Haanen JBAG; Rawson RV; van de Wiel BA; van de Poll-Franse LV; Scolyer RA; Boekhout AH; Long GV; Blank CU
    Nat Med; 2022 Jun; 28(6):1178-1188. PubMed ID: 35661157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
    Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
    Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.
    van Akkooi ACJ; Blank C; Eggermont AMM
    Eur J Cancer; 2023 Mar; 182():38-42. PubMed ID: 36738540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
    Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU
    Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU
    Nat Med; 2021 Feb; 27(2):256-263. PubMed ID: 33558721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for nodal recurrence after lymphadenectomy for melanoma.
    Pidhorecky I; Lee RJ; Proulx G; Kollmorgen DR; Jia C; Driscoll DL; Kraybill WG; Gibbs JF
    Ann Surg Oncol; 2001 Mar; 8(2):109-15. PubMed ID: 11258774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.
    Schermers B; Franke V; Rozeman EA; van de Wiel BA; Bruining A; Wouters MW; van Houdt WJ; Ten Haken B; Muller SH; Bierman C; Ruers TJM; Blank CU; van Akkooi ACJ
    Br J Surg; 2019 Apr; 106(5):519-522. PubMed ID: 30882901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
    Rawson RV; Adhikari C; Bierman C; Lo SN; Shklovskaya E; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Gonzalez M; Guminski AD; Tetzlaff MT; Stretch JR; Eriksson H; van Thienen JV; Wouters MW; Haanen JBAG; Klop WMC; Zuur CL; van Houdt WJ; Nieweg OE; Ch'ng S; Rizos H; Saw RPM; Spillane AJ; Wilmott JS; Blank CU; Long GV; van de Wiel BA; Scolyer RA
    Ann Oncol; 2021 Jun; 32(6):766-777. PubMed ID: 33744385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
    Braud A; Auloge P; Meyer N; Bouvrais C; Gharbi M; Lang H; Gangi A; Lipsker D
    Cardiovasc Intervent Radiol; 2024 May; 47(5):567-572. PubMed ID: 38570342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is therapeutic lymph node dissection of value for lymph node recurrence in melanoma?
    Wilson AK; Lourdault K; Ostad T; Stern S; Essner R
    Am J Surg; 2024 Feb; 228():258-263. PubMed ID: 37923660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients.
    Niebling MG; Wevers KP; Suurmeijer AJ; van Ginkel RJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Jan; 22(1):279-86. PubMed ID: 25008028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extent of surgery for stage III melanoma: how much is appropriate?
    Franke V; van Akkooi ACJ
    Lancet Oncol; 2019 Mar; 20(3):e167-e174. PubMed ID: 30842060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
    Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
    Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
    Tas F; Erturk K
    Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?
    Barbour S; Mark Smithers B; Allan C; Bayley G; Thomas J; Foote M; Burmeister B; Barbour AP
    Ann Surg Oncol; 2015 Nov; 22(12):4052-9. PubMed ID: 25582744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.